Amolimogene bepiplasmid, a DNA-based therapeutic encoding the E6 and E7 epitopes from HPV, for cervical and anal dysplasia

Current Opinion in Molecular Therapeutics

Volumn 10, Issue 6, 2008, Pages 622-628

  Alvarez Salas, L M ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AMOLIMOGENE BEPIPLASMID; DNA VACCINE; E6 EPITOPE; E7 EPITOPE; EPITOPE; PLACEBO; POLYMER; PROTEIN E7; UNCLASSIFIED DRUG; ZYC 101;

ANAL DYSPLASIA; ANUS DISEASE; BACKACHE; BINDING AFFINITY; CELL MIGRATION; CLINICAL TRIAL; CODON; COLUMN CHROMATOGRAPHY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HYBRID; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; INJECTION SITE REACTION; MOLECULAR CLONING; NONHUMAN; PLASMID; PROTEIN EXPRESSION; REVIEW; SINGLE DRUG DOSE; SORE THROAT; TREATMENT RESPONSE; TUMOR GROWTH; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; WART VIRUS;

ANUS NEOPLASMS; CANCER VACCINES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; EPITOPES; FEMALE; HUMANS; MULTICENTER STUDIES AS TOPIC; ONCOGENE PROTEINS, VIRAL; REPRESSOR PROTEINS; UTERINE CERVICAL DYSPLASIA; VACCINES, DNA; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 57349166695     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. 197917 Pangaea Pharmaceuticals Inc. Pangaea Pharmaceuticals Inc PRESS RELEASE 1996 January 28
2. 291910 Breakthrough cancer drug manufacturing alliance. Pangaea Pharmaceuticals Inc PRESS RELEASE 1998 July 17
3. 318867 Vaccination with cytotoxic T lymphocyte epitope protects against a tumor induced by human papillomavirus type 16-transformed cells. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJM, Kast WM EUR J IMMUNOL 1993 23 9 2242-2249
4. 397858 UCSF and ZYCOS collaborate in anal dysplasia study. ZYCOS Inc PRESS RELEASE 1999 October 18
5. 401262 A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J CLIN CANCER RES 2000 6 9 3406-3416
6. 421900 Immune responses are increased in ASIL patients following human papillomavirus (HPV) DNA immunization. Lathey JL, Matjevic M, Klencke B, Palefsky J, Urban RG, Hedley ML ICAAC 2001 41 Abs G-1564
7. 432243 Zycos completes enrollment of ZYC-101A phase II trial for cervical dysplasia. Zycos Inc PRESS RELEASE 2001 December 04
8. 457276 Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: A phase I study of ZYC101. Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, Thatcher J, Weinberg V, Wilson J, Darragh T, Jay N et al CLIN CANCER RES 2002 8 5 1028-1037
9. 496400 ZYC-101A profile. ZYCOS Inc COMPANY PUBLICATION 2003 July 09
10. 547508 Cancer statistics, 2000. Greenlee RT, Murray T, Bolden S, Wingo PA CA CANCER J CLIN 2000 50 1 7-33
11. 557147 MGI Pharma to acquire ZYCOS. MGI Pharma Inc PRESS RELEASE 2004 September 01
12. 932920 Strategies for human papillomavirus therapeutic vaccines and other therapies based on the E6 and E7 oncogenes. Govan VA ANN NY ACAD SCI 2005 1056 328-343
13. 932921 Dynamics of human papillomavirus infection between biopsy and excision of cervical intraepithelial neoplasia: Results from the ZYC101a protocol. Crum CP, Beach KJ, Hedley ML, Yuan L, Lee KR, Wright TC, Urban RG J INFECT DIS 2004 189 8 1348-1354
14. 932922 ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: A randomized controlled trial. Garcia F, Petry KU, Muderspach L, Gold MA, Braly P, Crum CP, Magill M, Silverman M, Urban RG, Hedley ML, Beach KJ OBSTET GYNECOL 2004 103 2 317-326
15. 932923 Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Sheets EE, Urban RG, Crum CP, Hedley ML, Politch JA, Gold MA, Muderspach LI, Cole GA, Crowley-Nowick PA AM J OBSTET GYNECOL 2003 188 4 916-926
16. 945882 Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Munoz N VACCINE 2008 26 Suppl 10 K1-K16
17. 945891 Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines. Stanley M, Gissmann L, Nardelli-Haefliger D VACCINE 2008 26 Suppl 10 K62-K67
18. 945899 Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Bezemer PD, Verheijen RH, Meijer CJ LANCET 2001 358 9295 1782-1783
19. 945900 Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. Stern PL J CLIN VIROL 2005 32 Suppl 1 S72-S81
20. 945903 DNA vaccines: Immunology, application, and optimization. Gurunathan S, Klinman DM, Seder RA ANNU REV IMMUNOL 2000 18 927-974
21. 945906 The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R J VIROL 1989 63 10 4417-4421
22. 945909 Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJ, Kast WM J IMMUNOL 1995 154 11 5934-5943
23. 945910 Efficacy and other milestones for human papillomavirus vaccine introduction. Pagliusi SR, Teresa Aguado M VACCINE 2004 23 5 569-578
24. 945912 Effect of human papillomavirus 16/18 L1 virus like particle vaccine among young women with preexisting infection: A randomized trial. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE et al J AM MED ASSOC 2007 298 7 743-753
25. 948180 Chapter 1: HPV in the etiology of human cancer. Munoz N, Castellsagué X, de González AB, Gissmann L VACCINE 2006 24 Suppl 3 S1-S10
26. 948224 HPV-related neoplasias in HIV-infected individuals. Del Mistro A, Chieco Bianchi L EUR J CANCER 2001 37 10 1227-1235
27. 948675 Study of amolimogene (ZYC101a) in patients with high grade cervical intraepithelial lesions of the uterine cervix. MGI Pharma Inc CLINICALTRIALS.GOV 2008
28. 949504 US-07097843: Immunogenic peptides from the HPV E7 protein. Urban RG, Chicz RM, Collins EJ, Hedley ML US PATENT 2006 August 29
29. 949506 US-20050100928: Nucleic acids encoding polyepitope polypeptides. Hedley ML, Urban RG, Chicz RM US PATENT 2005 May 12
30. 955771 Proposed International Nonproprietary Names: List 98. World Health Organization WHO DRUG INF 2007 21 4 317-369
31. 958027 Evaluating cervical neoplasia. LEEP as an alternative to cold knife conization. Simmons JR, Anderson L, Hernandez E, Heller PB J REPROD MED 1998 43 12 1007-1113
32. 958028 Risk factors for early cytologic abnormalities after loop electrosurgical excision procedure. Dietrich CS III, Yancey MK, Miyazawa K, Williams DL, Farley J OBSTET GYNECOL 2002 99 2 188-192
33. 958029 Recurrence of dysplasia after loop electrosurgical excision procedures with long-term follow-up. Gonzalez DI Jr, Zahn CM, Retzloff MG, Moore WF, Kost ER, Snyder RR AM J OBSTET GYNECOL 2001 184 3 315-321
34. 958031 Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development. O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG et al CLIN CANCER RES 2002 8 2 314-346
35. 958033 Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide. Jochmus I, Osen W, Altmann A, Buck G, Hofmann B, Schneider A, Gissmann L, Rammensee HG J GEN VIROL 1997 78 7 1689-1695
36. 958034 Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Frazer IH, Quinn M, Nicklin JL, Tan J, Perrin LC, Ng P, O'Connor VM, White O, Wendt N, Martin J, Crowley JM et al VACCINE 2004 23 2 172-181
37. 958035 Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of a phase I-II trial. van Driel WJ, Ressing ME, Kenter GG, Brandt RM, Krul EJ, van Rossum AB, Schuuring E, Offringa R, Bauknecht T, Tamm-Hermelink A, van Dam PA et al EUR J CANCER 1999 35 6 946-952
38. 958036 Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Baldwin PJ, van der Burg SH, Boswell CM, Offringa R, Hickling JK, Dobson J, Roberts JS, Latimer JA, Moseley RP, Coleman N, Stanley MA et al CLIN CANCER RES 2003 9 14 5205-5213
39. 958050 Chapter 7: Precancerous lesions of the cervix. Wright TC, Kurman RJ, Ferenczy A BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT 5th edition, (EDS: KURMAN RJ), Springer-Verlag, New York, NY, USA 2002 253-324